Is there a Bearish outlook for Incyte Corporation (NASDAQ:INCY) this week?

Incyte Corporation (NASDAQ:INCY) Logo
Investors sentiment decreased to 1.23 in Q2 2019. Its down 0.67, from 1.9 in 2019Q1. It is negative, as 39 investors sold Incyte Corporation shares while 128 reduced holdings. 65 funds opened positions while 140 raised stakes. 188.94 million shares or 0.12% more from 188.70 million shares in 2019Q1 were reported.
Ashford Cap Mgmt reported 151,318 shares. Parametric Assocs Ltd owns 0.03% invested in Incyte Corporation (NASDAQ:INCY) for 443,466 shares. Mengis Cap Mngmt Inc has invested 0.07% in Incyte Corporation (NASDAQ:INCY). 329,305 are owned by Federated Pa. Fmr Limited Liability reported 1.23 million shares stake. Moreover, Nomura Asset Management Limited has 0.03% invested in Incyte Corporation (NASDAQ:INCY) for 39,593 shares. Virtu Fin Ltd Co owns 3,050 shares for 0.02% of their portfolio. Los Angeles Management & Equity holds 0% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 4,261 shares. Ohio-based Cleararc Cap has invested 0.07% in Incyte Corporation (NASDAQ:INCY). Moreover, Northwestern Mutual Wealth Mngmt has 0% invested in Incyte Corporation (NASDAQ:INCY). Farmers & Merchants Invs stated it has 0% in Incyte Corporation (NASDAQ:INCY). Bnp Paribas Arbitrage reported 309,667 shares. The Connecticut-based Columbus Circle has invested 0.19% in Incyte Corporation (NASDAQ:INCY). Acadian Asset Mngmt Lc owns 1,184 shares or 0% of their US portfolio. Amica Mutual Ins Com invested in 0.05% or 4,795 shares.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Among 8 analysts covering Incyte (NASDAQ:INCY), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Incyte has $11100 highest and $7500 lowest target. $91.13’s average target is 19.23% above currents $76.43 stock price. Incyte had 15 analyst reports since April 2, 2019 according to SRatingsIntel. The rating was reinitiated by JMP Securities on Thursday, September 5 with “Market Outperform”. Morgan Stanley reinitiated Incyte Corporation (NASDAQ:INCY) rating on Thursday, September 5. Morgan Stanley has “Equal-Weight” rating and $8700 target. Nomura maintained Incyte Corporation (NASDAQ:INCY) on Wednesday, July 31 with “Buy” rating. The rating was upgraded by Oppenheimer on Thursday, September 5 to “Outperform”. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, July 31. The firm earned “Equal-Weight” rating on Friday, May 3 by Barclays Capital. Below is a list of Incyte Corporation (NASDAQ:INCY) latest ratings and price target changes.

12/09/2019 Broker: BMO Capital Markets Rating: Market Perform New Target: $85.0000 Initiates Coverage On
05/09/2019 Broker: JMP Securities Rating: Market Outperform New Target: $107.0000 Reinitiate
05/09/2019 Broker: Oppenheimer Old Rating: Perform New Rating: Outperform Old Target: $85.0000 New Target: $100.0000 Upgrade
05/09/2019 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $82.0000 New Target: $87.0000 Reinitiate
31/07/2019 Broker: Nomura Rating: Buy Old Target: $100.0000 New Target: $111.0000 Maintain
31/07/2019 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $81.0000 New Target: $82.0000 Maintain
22/05/2019 Broker: BidaskScore Rating: Hold Upgrade
21/05/2019 Broker: Credit Suisse Rating: Neutral New Target: $75.0000 Initiates Coverage On
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Old Target: $90.0000 New Target: $82.0000 Downgrade
03/05/2019 Broker: BidaskScore Rating: Sell Upgrade

The stock increased 0.47% or $0.36 during the last trading session, reaching $76.43. About 1.38 million shares traded or 15.90% up from the average. Incyte Corporation (NASDAQ:INCY) has risen 23.83% since September 13, 2018 and is uptrending. It has outperformed by 23.83% the S&P500.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $16.44 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It has a 53.79 P/E ratio. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

More notable recent Incyte Corporation (NASDAQ:INCY) news were published by: Finance.Yahoo.com which released: “Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet? – Yahoo Finance” on August 13, 2019, also Finance.Yahoo.com with their article: “Why I Like Incyte Corporation (NASDAQ:INCY) – Yahoo Finance” published on May 20, 2019, Nasdaq.com published: “Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer – Nasdaq” on August 19, 2019. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: Nasdaq.com and their article: “Nasdaq 100 Movers: ALGN, INCY – Nasdaq” published on June 17, 2019 as well as Seekingalpha.com‘s news article titled: “Incyte Q2 Earnings Preview – Seeking Alpha” with publication date: July 29, 2019.

Incyte Corporation (NASDAQ:INCY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.